A Flawed Study Shows How Little We Understand Crispr's Effects
b'Biotech has been betting big on Crispr, the gene-editing technique that promises to snip away some of humanity\\u2019s worst diseases. But last May, a small case study suggested the much-hyped technology might actually be quite dangerous\\u2014and pop went the Crispr bubble, briefly tanking shares of Crispr companies like Editas Medicine, Intellia Therapeutics, and Crispr Therapeutics.\\nLearn more about your ad choices. Visit podcastchoices.com/adchoices'